LOGIN
Teriparatide increases hip & spine BMD, particularly in type I osteogenesis imperfecta
May 2014
Teriparatide increases hip & spine BMD, particularly in type I osteogenesis imperfecta
Study Type:Therapy
OE Level Evidence:2
Journal Level of Evidence:N/A
Evaluation of teriparatide treatment in adults with osteogenesis imperfecta
J Clin Invest. 2014 Feb 3;124(2):491-8. doi: 10.1172/JCI71101.Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here
Synopsis
79 patients with osteogenesis imperfecta (OI) were randomized to receive either teriparatide (recombinant human parathyroid hormone) or a placebo administered subcutaneously daily for 18 months. The purpose of this proof-of-concept study was to determine whether teriparatide increased bone formation and positively affected skeletal mass and strength versus a placebo. The results at 18 months indic...
To view the full content, login to your account,
or start your 30-day FREE Trial today.
FREE TRIAL
LOGIN
Forgot Password?
Explore some of our unlocked ACE Reports below!
Learn about our AI Driven
High Impact Search Feature
Our AI driven High Impact metric calculates the impact an article will have by considering both the publishing journal and the content of the article itself. Built using the latest advances in natural language processing, OE High Impact predicts an article’s future number of citations better than impact factor alone.
Continue
Join the Conversation
Please Login or Join to leave comments.